Bio-Techne
American life sciences company From Wikipedia, the free encyclopedia
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.[1]
 | |
| Formerly | Research and Diagnostic Systems, Inc. (1976–1985) Techne Corporation (1985–2014) |
|---|---|
| Company type | Public |
| Industry | Biotechnology |
| Founded | 1976 |
| Founder | Roger C. Lucas |
| Headquarters | Minneapolis, Minnesota, U.S. |
Key people | |
| Products |
|
| Revenue | US$1.16 billion (2024) |
| US$207 million (2024) | |
| US$168 million (2024) | |
| Total assets | US$2.70 billion (2024) |
| Total equity | US$2.07 billion (2024) |
Number of employees | 3,100 (2024) |
| Website | bio-techne |
| Footnotes / references [1] | |
History
Summarize
Perspective
The company was founded in 1976 by Roger C. Lucas as Research and Diagnostic Systems, Inc. In 1985, it merged into Techne Corporation and became a public company.[1]
In March 2013, Charles (Chuck) Kummeth was named chief executive officer of the company.[2]
In July 2013, the company acquired Bionostics for $104 million.[3][4]
In February 2014, the company changed its name to Bio-Techne.[5]
In April 2014, the company agreed to acquire Shanghai PrimeGene Bio-Tech Company (PrimeGene).[6][7]
In July 2014, the company acquired Novus Biologicals for $60 million.[8][9][10]
In August 2014, the company acquired ProteinSimple for $300 million.[11]
In November 2014, the company agreed to acquire CyVek for $60 million plus up to an additional $135 million in earn-out payments.[12][13][14]
In June 2015, the company agreed to acquire Cliniqa Corporation.[15][16]
In March 2016, the company acquired Zephyrus Biosciences.[17][18][19]
In July 2016, the company acquired Space Import-Export.[20]
In August 2016, company acquired Advanced Cell Diagnostics for $250 million plus an additional $75 million in possible milestone payments.[21][22][23]
In September 2017, the company acquired Trevigen.[24][25]
In January 2018, the company acquired Atlanta Biologicals.[26][27]
In June 2018, the company agreed to acquire Quad Technologies.[28][29]
In August 2018, the company acquired Exosome Diagnostics for $250 million plus up to an additional $325 million in milestone payments.[30]
In June 2019, the company acquired B-Mogen.[31][32]
In April 2021, the company acquired Asuragen for $215 million plus up to an additional $105 million in milestone payments.[33]
In June 2022, the business announced it would acquire Namocell Inc.[34]
In June 2023, Bio-Techne announced it would acquire Lunaphore Technologies SA,[35] the transaction was completed the following month[36]
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.